He. Kuppers et al., PLACEBO-CONTROLLED COMPARISON OF THE EFFICACY AND TOLERABILITY OF ONCE-DAILY MOXONIDINE AND ENALAPRIL IN MILD-TO-MODERATE ESSENTIAL-HYPERTENSION, Journal of hypertension, 15(1), 1997, pp. 93-97
Objectives To compare the antihypertensive efficacy and tolerability o
f the imidazoline I, receptor agonist moxonidine, a centrally acting a
ntihypertensive, with the angiotensin converting enzyme inhibitor enal
april. Design An 8-week, double-blind, randomized, placebo-controlled
study involving 140 outpatients with mild-to-moderate essential hypert
ension. Methods Outpatients with WHO stage I or II hypertension were e
nrolled in the study, After a 4-week placebo-controlled stabilization
phase patients were allocated randomly to placebo, 0.2 mg moxonidine o
nce a day or 5 mg enalapril once a day for 2 weeks. Dosages were then
doubled to 0.4 mg moxonidine once a day or 10 mg enalapril once a day
for a further 6 weeks, Blood pressure responses to therapy were measur
ed by conventional office techniques and by 24 h ambulatory blood pres
sure monitoring, Results The mean reduction in sitting blood pressure
with moxonidine was similar to that with enalapril (19.5 +/- 16.0/12.3
+/- 8.7 versus 18.9 +/- 13.7/11.8 +/- 8.0 mmHg) and significantly sup
erior to that with placebo (-4.6 +/- 12.3/-4.7 +/- 6.8 mmHg, P < 0.001
). In addition to reducing blood pressure during conventional measurem
ents, moxonidine administration reduced blood pressure throughout 24 h
ambulatory measurements, The trough :peak ratio for moxonidine was 0.
7. Both moxonidine and enalapril were tolerated well, Conclusions Moxo
nidine is an effective and well-tolerated antihypertensive, at least a
s good as other established forms of antihypertensive medication. The
trough:peak ratio of 0.7 indicates that the drug will be effective adm
inistered once a day.